about
The 'permeome' of the malaria parasite: an overview of the membrane transport proteins of Plasmodium falciparum.Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance TransporterLocalisation of a candidate anion transporter to the surface of the malaria parasiteChloroquine transport via the malaria parasite's chloroquine resistance transporterThe malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamilyMultiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sitesSodium-dependent uptake of inorganic phosphate by the intracellular malaria parasiteA lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparumThe Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic ScreensChlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite's chloroquine resistance transporterQuinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum1H-NMR metabolite profiles of different strains of Plasmodium falciparum.Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance.Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities.Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents.Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT).Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs.A series of structurally simple chloroquine chemosensitizing dibemethin derivatives that inhibit chloroquine transport by PfCRT.Functional characteristics of the malaria parasite's "chloroquine resistance transporter": implications for chemotherapy.Identification of novel membrane proteins by searching for patterns in hydropathy profiles.Membrane transport proteins of the malaria parasite.Methionine transport in the malaria parasite Plasmodium falciparum.Transport of the essential nutrient isoleucine in human erythrocytes infected with the malaria parasite Plasmodium falciparum.Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasiteThe transportome of the malaria parasite.
P50
Q24797363-C02EEB63-89C6-4C2A-8A03-A9543DCC193FQ28552775-88D2912F-2E6B-4B42-9F57-F2A33C93DEA1Q30041168-7D8986C3-4FF4-4B48-9D55-C5436C23C4AEQ30041673-996ACC98-D890-4175-A959-F34026056A2BQ30041677-02327103-FD0D-4547-86A2-64CC2F1949F2Q30041687-DEFDB40A-A7AE-4AB6-B0E2-20E323D83E7BQ30042201-E26FDBE0-F119-4BD1-BC03-2BBF5EDD5BD4Q30042958-1C2C792E-25D0-4354-AE5F-071BD76630E3Q30042965-1539039F-6D44-4F9A-9752-1A2DB8F6DBFFQ33636449-B146583B-314D-45AF-B864-CF97497BCADAQ33674606-F4F980F3-0F96-43B0-93A0-E9B13CE5BC01Q33797050-BD20587F-AE23-4192-925C-784337D05049Q34554760-9856B27B-B960-4E03-9680-C3500BAF297FQ35941244-536CC85B-25A2-4E6F-849A-AF9C57842E15Q36090706-73606D27-029A-4F77-96E5-5E66F79F92C3Q36106723-BBBDC042-9290-4E40-9954-246B361674A2Q36919648-CCB00ACB-43CA-47CF-96F5-FC3B56C10AE0Q37979631-4BD72A6E-4532-4493-8F38-A92691B7065BQ39245950-51FC2468-8DD6-44B7-93C6-588B6F422A63Q39316530-A48456B1-3FAC-455E-8DA5-4E28E8B56E79Q39482802-0148FEE3-C509-4C10-90C9-CA1C2EC49612Q41916522-9946C6F2-8952-4CC5-A9CF-CEAD54F26802Q41933273-42ED8ADB-B571-481E-B4F4-2D09CE528E47Q41934123-66A16005-502D-4D80-A81B-5F58D5922B19Q43977215-E3AF9C9A-6EB6-4867-985D-E4FD636C1381Q47915147-7AB0A308-3FEA-4EE3-A290-6A3E15EF0C40Q47954895-679FF8B9-D751-4ABA-82A1-9D762E3B6881Q48036540-6AAE7F64-5971-45A0-8BEA-E7F561D861B4Q56341986-8D076311-FD69-4B4F-ACD2-8986B1496028Q85415936-9314FB5F-5309-4096-9C15-1E3EA690A00F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rowena Martin
@ast
Rowena Martin
@en
Rowena Martin
@es
Rowena Martin
@nl
Rowena Martin
@sl
type
label
Rowena Martin
@ast
Rowena Martin
@en
Rowena Martin
@es
Rowena Martin
@nl
Rowena Martin
@sl
altLabel
Rowena E Martin
@en
prefLabel
Rowena Martin
@ast
Rowena Martin
@en
Rowena Martin
@es
Rowena Martin
@nl
Rowena Martin
@sl
P1053
C-9992-2009
P106
P1960
WcKe094AAAAJ
P21
P31
P3829
P4012
P496
0000-0001-7408-5295